Kotak MF crosses 5% in Molbio Diagnostics via open market

Creeping Acquisition Near ThresholdOwnership Changes View source PDF Explain this filing

MOLBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹1442.00

prior close

₹1417.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+2.0% vs market

On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.4

15m

+0.4

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+2.1+0.2+2.0

Next day

+1.6+0.9+0.7

-0.9-0.8-0.1

+8.7-0.1+8.8

-0.5-1.7+1.3

-8.3-4.3-4.0

-13.7-7.5-6.2

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kotak Mahindra Mutual Fund acquired 5,70,000 equity shares (0.49%) of Molbio Diagnostics through open market on October 8, 2026. Its holding went from 4.99% (57,49,083 shares) to 5.48% (63,19,083 shares), crossing the 5% SAST disclosure threshold. KMMF is not part of the promoter group.

Likely market impact

Institutional confidence rising as a major mutual fund raised its stake above the 5% disclosure mark, a mildly positive sentiment signal.